Implementing antiobesity treatment in a patient with a mood disorder.
作者信息
Taylor Valerie H
机构信息
Department of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, Ont.
出版信息
J Psychiatry Neurosci. 2008 Nov;33(6):E1-2.
Abstract
摘要
相似文献
1
Implementing antiobesity treatment in a patient with a mood disorder.对患有情绪障碍的患者实施抗肥胖治疗。
J Psychiatry Neurosci. 2008 Nov;33(6):E1-2.
2
[Weight reduction. Antiobesity drug treatment in type-2 diabetics].[体重减轻。2型糖尿病患者的抗肥胖药物治疗]
Pharm Unserer Zeit. 2002;31(3):300-7. doi: 10.1002/1615-1003(200205)31:3<300::AID-PAUZ300>3.0.CO;2-C.
3
[No progress without the physician in therapy of obesity].肥胖治疗若无医生参与则无进展。
MMW Fortschr Med. 2000 Jan 27;142(4):35-6.
4
The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):e43-4. doi: 10.1016/j.numecd.2008.04.002. Epub 2008 Aug 3.
5
Prevention and management of obesity: pharmacology .肥胖症的预防与管理：药理学
Proc Nutr Soc. 2000 Aug;59(3):413.
6
Pharmacological therapy of obesity: past, present, and future.
J Clin Endocrinol Metab. 2003 Jun;88(6):2462-9. doi: 10.1210/jc.2003-030151.
7
The new role of pharmacotherapy for weight reduction in obesity.药物治疗在肥胖症减重方面的新作用。
Int J Clin Pract. 2002 Nov;56(9):683-6.
8
Long-term medication use and weight loss maintenance: an observational study.长期药物使用与体重减轻维持：一项观察性研究。
Obes Res. 2001 Oct;9(10):652-3. doi: 10.1038/oby.2001.88.
9
Obesity, cardiovascular risk and pharmacotherapy.肥胖、心血管风险与药物治疗。
Blood Press. 2002;11(5):260-2. doi: 10.1080/080370502320779458.
10
Pharmacotherapy for obesity--promise and uncertainty.肥胖症的药物治疗——前景与不确定性。
N Engl J Med. 2005 Nov 17;353(20):2187-9. doi: 10.1056/NEJMe058243.
引用本文的文献
1
Risk Factors for Unhealthy Weight Gain and Obesity among Children with Autism Spectrum Disorder.自闭症谱系障碍儿童体重过度增加和肥胖的风险因素。
Int J Mol Sci. 2019 Jul 4;20(13):3285. doi: 10.3390/ijms20133285.
Zotero 插件